Cancer Research: The lessons to learn from COVID-19

Abstract

The COVID-19 pandemic has caused widespread disruption of cancer clinical trials due to the restrictions on non-essential services and the re-allocation of resources, and at the same time the urgent global effort towards discovering therapies that treat or prevent COVID-19 infection has led to shortening of traditional regulatory timelines. This experience should stimulate similar urgency in the way future cancer research is conducted.